AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 52 min read$BSX

Mahoney Michael F purchased $9.0M of BSX

Mahoney Michael F (Chairman, President & CEO) purchased 186,240 shares of BOSTON SCIENTIFIC CORP (BSX) at $48.33 ($9.00M total) on 2026-08-03.

Original reporting
SEC EDGAR · Mahoney Michael F
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BSX
Bullish
medium confidence
Mentioned
$BSX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BSXBullishLow
01

Why it matters

The newest fact is the CEO’s open-market purchase of 186,240 shares at $48.3323 on 2026-08-03, filed on 2026-08-05.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not introduce new fundamentals in the provided text.

03

What to watch

The article provides no context on prior insider activity, option exercises, or whether the CEO’s holdings are already large, limiting inference from the $9.0M figure.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Boston Scientific (BSX).

Company-level read

Ticker impact

$BSXBullishMedium confidence
Context

Boston Scientific CEO Michael F Mahoney bought 186,240 shares in an open-market Form 4 transaction worth about $9.0M.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a primary-source Form 4 and the buy size is notable, but there is no accompanying guidance, deal, or operational update in the text.

Market effects

Sector

No sector-wide implications are disclosed; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be driven by diversification, liquidity needs, or routine planned activity; the filing notes no 10b5-1 plan but does not prove conviction.

Key entities

  • issuer
    Boston Scientific

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Michael F Mahoney

    Chairman, President and CEO who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BSX insider trading history →

Related articles

OCT 7
$BSXMed

Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructure

Boston Scientific (BSX) appointed Joseph M. Fitzgerald as COO, effective January 1, 2027, and restructured operations into three segments. The company is valued at $42.19, with a GF Value™ of $107.35, indicating a 60.7% undervaluation. BSX has a GF Score™ of 79, reflecting strong financial health and growth prospects, despite net insider selling and mixed guru activity.

gurufocus.com2 min
OCT 1
$BSXHigh

FDA Approves SpaceOAR Flex Hydrogel Rectal Spacer

FDA cleared Boston Scientific's SpaceOAR Flex Hydrogel, a rectal spacer for prostate cancer radiation therapy. The company claims it offers simpler setup and flexible delivery. Interim trial data showed 92.4% of patients had a 25% reduction in rectal radiation dose. Boston Scientific funded the study.

renalandurologynews.com2 min
SEP 30
$BSXMedAI 8/10

Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

Boston Scientific reported mixed Q2 2026 results, with Endoscopy sales up 7% YoY and Neuromodulation up 12%, but Urology underperforming. The company received FDA clearance for RIVOS and plans key launches to boost Urology growth. BSX shares fell 30.2% over six months, trading at a forward P/S ratio of 2.89. Medtronic and Teleflex also reported recent developments.

zacks.com2 min